RecruitingNCT01884051
Hormonal, Metabolic, and Signaling Interactions in PAH
Hormonal, Metabolic, and Signaling Interaction in Pulmonary Arterial Hypertension
Sponsor
Vanderbilt University Medical Center
Enrollment
1,899 participants
Start Date
Sep 1, 2012
Study Type
OBSERVATIONAL
Conditions
Summary
Our hypothesis is that optimal treatment of the dysfunctional metabolic pathways which underlie PAH will improve pulmonary vascular function and consequences of the disease.
Eligibility
Max Age: 90 Years
Plain Language Summary
Simplified for easier understanding
This study examines the hormonal, metabolic, and cellular signaling patterns in people with pulmonary arterial hypertension (PAH) — high blood pressure in the lungs — to understand why the disease develops and why it affects women more often than men.
**You may be eligible if...**
- You have been diagnosed with idiopathic, heritable, or associated pulmonary arterial hypertension (or are a family member of someone with these diagnoses)
- You are generally between 0 and 90 years old (specific sub-studies have narrower age ranges)
- You have access to the clinic for testing and can tolerate fasting before some tests (for certain sub-studies)
**You may NOT be eligible if...**
- You have a different type of diagnosis unrelated to PAH
- You exceed the age limits for the specific sub-study
- You are unable to fast or travel to the clinic as needed
Talk to your doctor to see if this trial is right for you.
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT01884051
Related Trials
Risk and Resilience in Pulmonary Arterial Hypertension and Genetically Susceptible Individuals
NCT055847221 location
129 Xenon MRI as a Biomarker for Diagnosis and Response to Therapy in Pulmonary Arterial Hypertension (PAH)
NCT061042281 location
Right Ventricle Lipid in Pulmonary Arterial Hypertension (PAH)
NCT054625741 location